About: Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Sector: Healthcare
Industry: Biotechnology
Latest price: $18.29 (-2.51%)
IMNM NASDAQ Immunome Inc
Immunome Inc share price
Atividade de preço de IMNM
Último preço
$ 18,290
Variação (24h)
-0,47 USD (2,51%)
Volume
876.76K
Volume (média 4 sem.)
-
Abertura
$ 18,88
Variação do dia
$ 18,11 - $ 19,30
Fechamento anterior
$ 18,76
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
IMNM price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals